大多数 R/R CLL 参与者在接受 Venetoclax、acalabrutinib 和 obinutuzumab 治疗后，MRD 检测不到

{"title":"大多数 R/R CLL 参与者在接受 Venetoclax、acalabrutinib 和 obinutuzumab 治疗后，MRD 检测不到","authors":"Robert van den Heuvel","doi":"10.55788/11dff369","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":517344,"journal":{"name":"Medicom Conference Report ASH 2023","volume":"23 20","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Undetectable MRD on maintenance venetoclax, acalabrutinib, and obinutuzumab in the majority of R/R CLL participants\",\"authors\":\"Robert van den Heuvel\",\"doi\":\"10.55788/11dff369\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":517344,\"journal\":{\"name\":\"Medicom Conference Report ASH 2023\",\"volume\":\"23 20\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicom Conference Report ASH 2023\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.55788/11dff369\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicom Conference Report ASH 2023","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.55788/11dff369","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}